Treatment of MM cells with non-targeting (NT) or ILF2 targeting oligonucleotide antisenses (ASOs)

To gain insights into the molecular mechanisms by which myeloma cells overcome ILF2 ASO-induced DNA damage activation, we performed bulk RNA sequencing (RNA-seq) analysis of ASO-treated KMS11 and JJN3 cells at early (1 week) and late (3 weeks) treatment time points. MM cells were treated with NT (control) or ILF2 ASOs for 1 or 3 weeks to evaluate whether they could overcome ILF2 ASO-induced DNA damage. Three replicates were included for each.

为深入解析骨髓瘤细胞克服ILF2反义寡核苷酸（Antisense Oligonucleotide，ASO）诱导的DNA损伤激活的分子机制，我们对经ASO处理的KMS11与JJN3细胞，在处理早期（1周）和晚期（3周）两个时间点开展批量RNA测序（RNA-seq）分析。本实验中，多发性骨髓瘤（Multiple Myeloma，MM）细胞分别以NT（对照）或ILF2 ASO处理1周或3周，以验证细胞是否能够克服ILF2 ASO诱导的DNA损伤；每组均设置3次生物学重复。